Global Recurrent Glioblastoma Multiforme Treatment Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
- Published Date: 2021-04-23
- Report ID: 106029
- Pages: 110
-
Format:
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Recurrent Glioblastoma Multiforme Treatment market in this environment.
In terms of revenue, this research report indicated that the global Recurrent Glioblastoma Multiforme Treatment market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Recurrent Glioblastoma Multiforme Treatment industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Boehringer Ingelheim GmbH aims at producing XX K Units Recurrent Glioblastoma Multiforme Treatment in 2020, with XX % production to take place in global market, Boston Biomedical, Inc. accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Recurrent Glioblastoma Multiforme Treatment Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Recurrent Glioblastoma Multiforme Treatment Market
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cantex Pharmaceuticals, Inc.
Cavion LLC
Celldex Therapeutics, Inc.
Coherus BioSciences, Inc.
Cortice Biosciences, Inc.
Eisai
Eli Lilly and Company
EnGeneIC Ltd
ERC Belgium SA
GenSpera, Inc.
Genzyme Corporation
GW Pharmaceuticals Plc
ImmunoCellular Therapeutics, Ltd.
...
Major Type of Recurrent Glioblastoma Multiforme Treatment Covered in Prudent Markets report:
AU-105
Axitinib
AXL-1717
AZD-7451
Others
Application Segments Covered in Prudent Markets Market
Hospital
Clinic
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Recurrent Glioblastoma Multiforme Treatment Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 AU-105 -Product Introduction and Major Manufacturers
1.1.2 Axitinib -Product Introduction and Major Manufacturers
1.1.3 AXL-1717 -Product Introduction and Major Manufacturers
1.1.4 AZD-7451 -Product Introduction and Major Manufacturers
1.1.5 Others -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Recurrent Glioblastoma Multiforme Treatment Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis
3.1 China Recurrent Glioblastoma Multiforme Treatment Market
3.1.1 Top Companies leading Recurrent Glioblastoma Multiforme Treatment Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Recurrent Glioblastoma Multiforme Treatment Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)
3.2 EU Recurrent Glioblastoma Multiforme Treatment Market
3.2.1 Top Companies leading Recurrent Glioblastoma Multiforme Treatment Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Recurrent Glioblastoma Multiforme Treatment Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)
3.3 USA Recurrent Glioblastoma Multiforme Treatment Market
3.3.1 Top Companies leading Recurrent Glioblastoma Multiforme Treatment Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Recurrent Glioblastoma Multiforme Treatment Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)
3.4 Japan Recurrent Glioblastoma Multiforme Treatment Market
3.4.1 Top Companies leading Recurrent Glioblastoma Multiforme Treatment Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Recurrent Glioblastoma Multiforme Treatment Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)
3.5 India Recurrent Glioblastoma Multiforme Treatment Market
3.5.1 Top Companies leading Recurrent Glioblastoma Multiforme Treatment Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Recurrent Glioblastoma Multiforme Treatment Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)
3.6 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market
3.6.1 Top Companies leading Recurrent Glioblastoma Multiforme Treatment Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Recurrent Glioblastoma Multiforme Treatment Market
3.7.1 Top Companies leading Recurrent Glioblastoma Multiforme Treatment Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Recurrent Glioblastoma Multiforme Treatment Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)
4.1 Recurrent Glioblastoma Multiforme Treatment Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Recurrent Glioblastoma Multiforme Treatment Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)
5.1 Global Recurrent Glioblastoma Multiforme Treatment Sales and Growth Rate (2021-2027)
5.2 Global Recurrent Glioblastoma Multiforme Treatment Sales Value and Growth Rate (2021-2027)
6 Recurrent Glioblastoma Multiforme Treatment Competitive Analysis
6.1 Boehringer Ingelheim GmbH
6.1.1 Boehringer Ingelheim GmbH Company Profiles
6.1.2 Boehringer Ingelheim GmbH Product Introduction
6.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Production, Revenue (2016-2021)
6.1.4 SWOT Analysis
6.2 Boston Biomedical, Inc.
6.2.1 Boston Biomedical, Inc. Company Profiles
6.2.2 Boston Biomedical, Inc. Product Introduction
6.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue (2016-2021)
6.2.4 SWOT Analysis
6.3 Bristol-Myers Squibb Company
6.3.1 Bristol-Myers Squibb Company Company Profiles
6.3.2 Bristol-Myers Squibb Company Product Introduction
6.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Production, Revenue (2016-2021)
6.3.4 SWOT Analysis
6.4 Cantex Pharmaceuticals, Inc.
6.4.1 Cantex Pharmaceuticals, Inc. Company Profiles
6.4.2 Cantex Pharmaceuticals, Inc. Product Introduction
6.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue (2016-2021)
6.4.4 SWOT Analysis
6.5 Cavion LLC
6.5.1 Cavion LLC Company Profiles
6.5.2 Cavion LLC Product Introduction
6.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6 Celldex Therapeutics, Inc.
6.6.1 Celldex Therapeutics, Inc. Company Profiles
6.6.2 Celldex Therapeutics, Inc. Product Introduction
6.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 Coherus BioSciences, Inc.
6.7.1 Coherus BioSciences, Inc. Company Profiles
6.7.2 Coherus BioSciences, Inc. Product Introduction
6.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 Cortice Biosciences, Inc.
6.8.1 Cortice Biosciences, Inc. Company Profiles
6.8.2 Cortice Biosciences, Inc. Product Introduction
6.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
6.9 Eisai
6.9.1 Eisai Company Profiles
6.9.2 Eisai Product Introduction
6.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Production, Revenue (2016-2021)
6.9.4 SWOT Analysis
6.10 Eli Lilly and Company
6.10.1 Eli Lilly and Company Company Profiles
6.10.2 Eli Lilly and Company Product Introduction
6.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Production, Revenue (2016-2021)
6.10.4 SWOT Analysis
6.11 EnGeneIC Ltd
6.12 ERC Belgium SA
6.13 GenSpera, Inc.
6.14 Genzyme Corporation
6.15 GW Pharmaceuticals Plc
6.16 ImmunoCellular Therapeutics, Ltd.
7 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
